Sai-Hong Ignatius Ou (Sai-Hong I Ou, Saihong Ignatius Ou)

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 49

Top Topics

Systematic Review

Tyrosine Kinase

Small Cell Lung Cancer

Top Venues

Lung Cancer (Auckland, N.Z.)

Cancer discovery

Clinical cancer research : an official journal of the American Association for Cancer Research

Journal of clinical oncology : official journal of the American Society of Clinical Oncology

This page only lists publications with an associated author ORCID identifier.

Publications

Jii Bum Lee, Sai-Hong Ignatius Ou
ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR -Mutated NSCLC? Lung Cancer (Auckland, N.Z.) 15 (2024)
Alexandria T M Lee, Sai-Hong Ignatius Ou
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver. Lung Cancer (Auckland, N.Z.) 15 (2024)
Sai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, Thanyanan Reungwetwattana, Myung-Ju Ahn, Darren W T Lim, Edgardo S Santos, Elaine Shum, Sally C M Lau, Jii Bum Lee, Antonio Calles, Fengying Wu, Gilberto Lopes, Virote Sriuranpong, Junko Tanizaki, Hidehito Horinouchi, Marina C Garassino, Sanjay Popat, Benjamin Besse, Rafael Rosell, Ross A Soo
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey. Lung Cancer (Auckland, N.Z.) 15 (2024)
Faustine X Luo, Sai-Hong Ignatius Ou
"ACHILLES" Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834). Lung Cancer (Auckland, N.Z.) 15 (2024)
Natthaya Triphuridet, Misako Nagasaka, Elaine Shum, Sai-Hong Ignatius Ou
Race, age at diagnosis and histological characteristics of lung cancer in never-smokers (LCINS) and ever-smokers in low-dose computed tomography (LDCT) screening: a systematic review and meta-analysis. Translational lung cancer research 13 (5) (2024)
Faustine X Luo, Sai-Hong Ignatius Ou
"ACHILLES" Heel No More? Afatinib at 40 Mg Once Daily is Superior to Platinum-Based Chemotherapy in EGFR Uncommon (G719X, S768I, and L861Q) Mutations (ACHILLES/TORG1834). Lung Cancer (Auckland, N.Z.) 15 (2024)
Alexandria T M Lee, Sai-Hong Ignatius Ou
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive ( RET +) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC. Lung Cancer (Auckland, N.Z.) 15 (2024)
Natthaya Triphuridet, Misako Nagasaka, Elaine Shum, Sai-Hong Ignatius Ou
Race, age at diagnosis and histological characteristics of lung cancer in never-smokers (LCINS) and ever-smokers in low-dose computed tomography (LDCT) screening: a systematic review and meta-analysis. Translational lung cancer research 13 (5) (2024)
Sai-Hong Ignatius Ou, Xiuning Le, Misako Nagasaka, Thanyanan Reungwetwattana, Myung-Ju Ahn, Darren W T Lim, Edgardo S Santos, Elaine Shum, Sally C M Lau, Jii Bum Lee, Antonio Calles, Fengying Wu, Gilberto Lopes, Virote Sriuranpong, Junko Tanizaki, Hidehito Horinouchi, Marina C Garassino, Sanjay Popat, Benjamin Besse, Rafael Rosell, Ross A Soo
Top 20 EGFR+ NSCLC Clinical and Translational Science Papers That Shaped the 20 Years Since the Discovery of Activating EGFR Mutations in NSCLC. An Editor-in-Chief Expert Panel Consensus Survey. Lung Cancer (Auckland, N.Z.) 15 (2024)
Jii Bum Lee, Sai-Hong Ignatius Ou
ATTLAS, IMpower151 and ORIENT-31: Dusting off IMpower150 for Post-Osimertinib in EGFR -Mutated NSCLC? Lung Cancer (Auckland, N.Z.) 15 (2024)
Alexandria T M Lee, Sai-Hong Ignatius Ou
LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced RET Fusion-Positive ( RET +) NSCLC, Another Unique Never-Smoker Predominant Molecular Subtype of NSCLC. Lung Cancer (Auckland, N.Z.) 15 (2024)
Alexandria T M Lee, Sai-Hong Ignatius Ou
Overcoming Central β-Sheet #6 (Cβ6) ALK Mutation (L1256F), TP53 Mutations and Short Forms of EML4-ALK v3/b and v5a/b Splice Variants are the Unmet Need That a Re-Imagined 5th-Generation (5G) ALK TKI Must Deliver. Lung Cancer (Auckland, N.Z.) 15 (2024)
Danielle Brazel, Sai-Hong Ignatius Ou
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC? Lung Cancer (Auckland, N.Z.) 14 (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Alexandria T M Lee, Sai-Hong Ignatius Ou
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting. Lung Cancer (Auckland, N.Z.) 14 (2023)
Danielle Brazel, Sai-Hong Ignatius Ou
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC? Lung Cancer (Auckland, N.Z.) 14 (2023)
Danielle Brazel, Sai-Hong Ignatius Ou
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC? Lung Cancer (Auckland, N.Z.) 14 (2023)
Danielle Brazel, Sai-Hong Ignatius Ou, Misako Nagasaka
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno. Lung Cancer (Auckland, N.Z.) 14 (2023)
Alexandria T M Lee, Sai-Hong Ignatius Ou
ALESIA 5-Year Update: Alectinib at 600 mg Twice Daily Gives Lorlatinib a Run for Its Money in Asia. Lung Cancer (Auckland, N.Z.) 14 (2023)
Danielle Brazel, Sai-Hong Ignatius Ou, Misako Nagasaka
Tiragolumab (Anti-TIGIT) in SCLC: Skyscraper-02, a Towering Inferno. Lung Cancer (Auckland, N.Z.) 14 (2023)
Alexandria T M Lee, Sai-Hong Ignatius Ou
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting. Lung Cancer (Auckland, N.Z.) 14 (2023)
Alexandria T M Lee, Sai-Hong Ignatius Ou
From ASCEND-5 to ALUR to ALTA-3, an Anti-Climactic End to the Era of Randomized Phase 3 Trials of Next-Generation ALK TKIs in the Crizotinib-Refractory Setting. Lung Cancer (Auckland, N.Z.) 14 (2023)
Jayesh Desai, Guzman Alonso, Se Hyun Kim, Andres Cervantes, Thomas Benjamin Karasic, Laura Medina, Einat Shacham-Shmueli, Rasha Cosman, Alejandro Falcón Gonzalez, Eelke Gort, Tormod Kyrre Guren, Erminia Massarelli, Wilson H Miller, Luis Paz-Ares, Hans Prenen, Alessio Amatu, Chiara Cremolini, Tae Won Kim, Victor Moreno, Sai-Hong Ignatius Ou, Alessandro Passardi, Adrian Sacher, Armando Santoro, Rafal Stec, Susanna Ulahannan, Kathryn C Arbour, Patricia M LoRusso, Jia Luo, Manish R Patel, Yoonha Choi, Zhen Shi, Sandhya Mandlekar, Mark T Lin, Stephanie Royer-Joo, Julie Chang, Tomi Jun, Neekesh V Dharia, Jennifer L Schutzman, null null, Sae-Won Han
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial. Nature medicine (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Danielle Brazel, Jennifer Kim, Sai-Hong Ignatius Ou
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C + NSCLC Enigma Code. Lung Cancer (Auckland, N.Z.) 14 (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Danielle Brazel, Sai-Hong Ignatius Ou
The Additional Exclusions of ROS1 Fusions (In Addition to EGFR Mutation and ALK Fusions) in the Cemiplimab NSCLC FDA Indication (EMPOWER-Lung 1 and -Lung 3). Catching Up with Current Scientific View of Immunotherapy in Never-Smoker Predominant Actionable Driver Mutation Positive NSCLC? Lung Cancer (Auckland, N.Z.) 14 (2023)
Misako Nagasaka, Yuichiro Ohe, Caicun Zhou, Chang-Min Choi, Nong Yang, Geoffrey Liu, Enriqueta Felip Font, Maurice Pérol, Benjamin Besse, Jorge J Nieva, Luis E Raez, Nathan A Pennell, Anastasios Dimou, Filippo de Marinis, Fortunato Ciardiello, Takashi Seto, Zheyi Hu, Max Pan, Weiqing Wang, Shuanglian Li, Sai-Hong Ignatius Ou
TRUST-II: a global phase II study of taletrectinib in ROS1 -positive non-small-cell lung cancer and other solid tumors. Future oncology (London, England) (2023)
Danielle Brazel, Jennifer Kim, Sai-Hong Ignatius Ou
CodeBreaK 200: Sotorasib (AMG510) Has Broken the KRAS G12C + NSCLC Enigma Code. Lung Cancer (Auckland, N.Z.) 14 (2023)
Misako Nagasaka, Sai-Hong Ignatius Ou
Stage as the Sole "Biomarker" for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091? Lung Cancer (Auckland, N.Z.) 14 (2023)
Byoung Chul Cho, Dong Wan Kim, Alexander I Spira, Jorge E Gomez, Eric B Haura, Sang-We Kim, Rachel E Sanborn, Eun Kyung Cho, Ki Hyeong Lee, Anna R Minchom, Jong-Seok Lee, Ji-Youn Han, Misako Nagasaka, Joshua K Sabari, Sai-Hong Ignatius Ou, Patricia Lorenzini, Joshua M Bauml, Joshua C Curtin, Amy Roshak, Grace Gao, John Xie, Meena Thayu, Roland E Knoblauch, Keunchil Park
Amivantamab plus lazertinib in osimertinib-relapsed EGFR-mutant advanced non-small cell lung cancer: a phase 1 trial. Nature medicine (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 Is a Selective, TRK-Sparing, and Brain-Penetrant Inhibitor of ROS1 Fusions and Secondary Resistance Mutations. Cancer discovery 13 (3) (2023)
Misako Nagasaka, Sai-Hong Ignatius Ou
Stage as the Sole "Biomarker" for Adjuvant Pembrolizumab in Resected Stage IB to IIIA NSCLC without Considerations for PD-L1 Expression Level, ALK/EGFR Mutational Status, and Prior Adjuvant Chemotherapy per FDA Approval Indications of PEARLS/Keynote-091? Lung Cancer (Auckland, N.Z.) 14 (2023)
Cloud P Paweletz, Grace A Heavey, Yanan Kuang, Emily Durlacher, Thian Kheoh, Richard C Chao, Alexander I Spira, Konstantinos Leventakos, Melissa Lynne Johnson, Sai-Hong Ignatius Ou, Gregory J Riely, Kenna Anderes, Wenjing Yang, James G Christensen, Pasi A Janne
Early changes in circulating cell free KRAS G12C predicts response to adagrasib in KRAS mutant non-small cell lung cancer patients. Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer discovery (2022)
Hui Wang, Zhi-Wei Li, Qiuxiang Ou, Xue Wu, Misako Nagasaka, Yang Shao, Sai-Hong Ignatius Ou, Yu Yang
NTRK fusion positive colorectal cancer is a unique subset of CRC with high TMB and microsatellite instability. Cancer medicine 11 (13) (2022)
Jessica K Lee, Smruthy Sivakumar, Alexa B Schrock, Russell Madison, David Fabrizio, Ole Gjoerup, Jeffrey S Ross, Garrett M Frampton, Pavel Napalkov, Meagan Montesion, Jennifer L Schutzman, Xin Ye, Priti S Hegde, Misako Nagasaka, Geoffrey R Oxnard, Ethan S Sokol, Sai-Hong Ignatius Ou, Zhen Shi
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ precision oncology 6 (1) (2022)
Rafal Dziadziuszko, Solange Peters, Tony Mok, D Ross Camidge, Shirish M Gadgeel, Sai-Hong Ignatius Ou, Krzysztof Konopa, Johannes Noé, Malgorzata Nowicka, Walter Bordogna, Peter N Morcos, Vlatka Smoljanovic, Alice T Shaw
Circulating Cell-free DNA as a Prognostic Biomarker in Patients with Advanced ALK+ Non-small Cell Lung Cancer in the Global Phase III ALEX Trial. Clinical cancer research : an official journal of the American Association for Cancer Research 28 (9) (2022)
Alexander E Drilon, Joshua C Horan, Anupong Tangpeerachaikul, Benjamin Besse, Sai-Hong Ignatius Ou, Shirish M Gadgeel, D Ross Camidge, Anthonie J van der Wekken, Linh Nguyen-Phuong, Adam Acker, Clare Keddy, Katelyn S Nicholson, Satoshi Yoda, Scot Mente, Yuting Sun, John R Soglia, Nancy E Kohl, James R Porter, Matthew D Shair, Viola W Zhu, Monika A Davare, Aaron N Hata, Henry E Pelish, Jessica J Lin
NVL-520 is a selective, TRK-sparing, and brain-penetrant inhibitor of ROS1 fusions and secondary resistance mutations. Cancer discovery (2022)
Shannon S Zhang, Sai-Hong Ignatius Ou
Spotlight on Furmonertinib (Alflutinib, AST2818). The Swiss Army Knife (del19, L858R, T790M, Exon 20 Insertions, "uncommon-G719X, S768I, L861Q") Among the Third-Generation EGFR TKIs? Lung Cancer (Auckland, N.Z.) 13 (2022)
Benjamin J Solomon, Todd M Bauer, Sai-Hong Ignatius Ou, Geoffrey Liu, Hidetoshi Hayashi, Alessandra Bearz, Konstantin Penkov, Yi-Long Wu, Arrieta Oscar, Jacek Jassem, Anna M Calella, Gerson Peltz, Anna Polli, Holger Thurm, Tony S K Mok
Post Hoc Analysis of Lorlatinib Intracranial Efficacy and Safety in Patients With ALK -Positive Advanced Non-Small-Cell Lung Cancer From the Phase III CROWN Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (31) (2022)
Jessica K Lee, Smruthy Sivakumar, Alexa B Schrock, Russell Madison, David Fabrizio, Ole Gjoerup, Jeffrey S Ross, Garrett M Frampton, Pavel Napalkov, Meagan Montesion, Jennifer L Schutzman, Xin Ye, Priti S Hegde, Misako Nagasaka, Geoffrey R Oxnard, Ethan S Sokol, Sai-Hong Ignatius Ou, Zhen Shi
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ precision oncology 6 (1) (2022)
Shannon S Zhang, Sai-Hong Ignatius Ou
Deconstructing ADAURA: It is Time to Forgo Adjuvant Platinum-Based Chemotherapy in Resected IB-IIIA EGFR+ NSCLC (Except with RB Alterations?) When Adopting Adjuvant Osimertinib. Lung Cancer (Auckland, N.Z.) 13 (2022)
Sai-Hong Ignatius Ou, Pasi A Janne, Ticiana A Leal, Igor I Rybkin, Joshua K Sabari, Minal A Barve, Lyudmila Bazhenova, Melissa Lynne Johnson, Karen L Velastegui, Cornelius Cilliers, James G Christensen, Xiaohong Yan, Richard C Chao, Kyriakos P Papadopoulos
First-in-Human Phase I/IB Dose-Finding Study of Adagrasib (MRTX849) in Patients With Advanced KRAS G12C Solid Tumors (KRYSTAL-1). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 40 (23) (2022)
Jessica K Lee, Smruthy Sivakumar, Alexa B Schrock, Russell Madison, David Fabrizio, Ole Gjoerup, Jeffrey S Ross, Garrett M Frampton, Pavel Napalkov, Meagan Montesion, Jennifer L Schutzman, Xin Ye, Priti S Hegde, Misako Nagasaka, Geoffrey R Oxnard, Ethan S Sokol, Sai-Hong Ignatius Ou, Zhen Shi
Comprehensive pan-cancer genomic landscape of KRAS altered cancers and real-world outcomes in solid tumors. NPJ precision oncology 6 (1) (2022)
Misako Nagasaka, Sai-Hong Ignatius Ou
ORIENT-31 as the Sakigake "Charging Samurai" Born of IMpower150 but Will MARIPOSA-2 IMPRESS in the "Meiji Modernization" of Post-3G EGFR TKI Progression? Lung Cancer (Auckland, N.Z.) 13 (2022)
Jessica J Lin, Noura J Choudhury, Satoshi Yoda, Viola W Zhu, Ted W Johnson, Ramin Sakhtemani, Ibiayi Dagogo-Jack, Subba R Digumarthy, Charlotte Lee, Andrew Do, Jennifer Peterson, Kylie Prutisto Chang, Wafa Malik, Harper G Hubbeling, Adam Langenbucher, Adam J Schoenfeld, Christina J Falcon, Jennifer S Temel, Lecia V Sequist, Beow Y Yeap, Jochen K Lennerz, Alice T Shaw, Michael S Lawrence, Sai-Hong Ignatius Ou, Aaron N Hata, Alexander E Drilon, Justin F Gainor
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research 27 (10) (2021)
Alexander E Drilon, Michael Duruisseaux, Ji-Youn Han, Masaoki Ito, Christina J Falcon, Soo-Ryum Yang, Yonina R Murciano-Goroff, Haiquan Chen, Morihito Okada, Miguel Ángel Molina-Vila, Marie Wislez, Philippe Brun, Clarisse Dupont, Eva Branden, Giulio Rossi, Alexa B Schrock, Siraj M Ali, Valérie Gounant, Fanny Magne, Torsten Gerriet Blum, Alison M Schram, Isabelle Monnet, Jin-Yuan Shih, Joshua K Sabari, Maurice Pérol, Viola W Zhu, Misako Nagasaka, Robert Doebele, D Ross Camidge, Maria Arcila, Sai-Hong Ignatius Ou, Denis Moro-Sibilot, Rafael Rosell, Lucia Anna Muscarella, Stephen V Liu, Jacques Cadranel
Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 39 (25) (2021)
Kyriakos P Papadopoulos, Erkut Hasan Borazanci, Alice T Shaw, Ryohei Katayama, Yuki Shimizu, Viola W Zhu, Thomas Yang Sun, Heather A Wakelee, Russell W Madison, Alexa B Schrock, Giorgio Senaldi, Naoki Nakao, Hiroyuki Hanzawa, Masaya Tachibana, Takeshi Isoyama, Kenji Nakamaru, Chenhui Deng, Meijing Li, Frank Fan, Qinying Zhao, Yanfei Gao, Takashi Seto, Pasi A Jänne, Sai-Hong Ignatius Ou
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors. Clinical cancer research : an official journal of the American Association for Cancer Research 26 (18) (2020)